United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

21 Aug 2017
Change (% chg)

$0.31 (+0.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Eli Lilly announces positive results for second phase 3 study of Lasmiditan for treatment of Migraine
Friday, 4 Aug 2017 06:45am EDT 

Aug 4 (Reuters) - Eli Lilly And Co ::Eli Lilly announces positive results for second phase 3 study of Lasmiditan for the acute treatment of Migraine.Lasmiditan met its primary endpoint in second phase 3 study spartan.Greater percentage of patients treated with Lasmiditan were migraine pain-free compared to placebo.Lasmiditan also met key secondary endpoint for spartan across all three studied doses.Plan to submit new drug application for Lasmiditan to U.S. FDA in second half of 2018.  Full Article

Lilly gets civil investigative demand from Minnesota AG for insulin product pricing‍​
Friday, 28 Jul 2017 12:04pm EDT 

July 28 (Reuters) - Eli Lilly And Co ::Says got civil investigative demand from Minnesota's office of Attorney General relating to pricing, sale of insulin products - SEC filing‍​.Says offices of attorneys general in California and Florida have requested information relating to pricing of company's insulin products.Says lost patent exclusivity for Strattera in the U.S. in May 2017, and generic versions of Strattera were approved in the same month.Entry of generic versions of Strattera has caused "rapid and severe" decline in revenue, which will have material adverse effect on results.In May, Japanese Patent Office resumed 1 of 2 remaining demands for invalidation of company's two vitamin regimen patents, brought by Nipro Corp.  Full Article

Eli lilly says seeks external early cancer assets
Tuesday, 25 Jul 2017 10:47am EDT 

July 25 (Reuters) - Eli Lilly And Co :Eli Lilly says intends to be more active seeking external preclinical and early stage immuno-oncology assets.Eli Lilly says plans to start Phase III baricitinib trial in psoriatic arthritis next year.  Full Article

Lilly reports second-quarter results
Tuesday, 25 Jul 2017 06:25am EDT 

July 25 (Reuters) - Eli Lilly And Co :Lilly reports second-quarter results.Q2 non-GAAP earnings per share $1.11.Q2 earnings per share $0.95.Sees FY 2017 revenue $22 billion to $22.5 billion.Q2 revenue $5.824 billion versus I/B/E/S view $5.6 billion.Q2 earnings per share view $1.05 -- Thomson Reuters I/B/E/S.Sees FY 2017 non-GAAP earnings per share $4.10 to $4.20.Sees FY 2017 earnings per share $2.51 to $2.61.FY2017 earnings per share view $4.12, revenue view $22.14 billion -- Thomson Reuters I/B/E/S.Eli Lilly And Co - worldwide Jardiance revenue during Q2 of 2017 was $103.2 million, an increase of 157 percent compared with Q2 of 2016.Says ‍company has raised 2017 non-GAAP EPS outlook​.Eli Lilly And Co - ‍providing an update to its oncology research and development strategy​.Eli Lilly And Co says qtrly Cymbalta sales $206.6 million versus $236.5 million.Eli Lilly And Co - for Q2 of 2017, Alimta generated worldwide revenue of $532.9 million, which decreased 12 percent compared with Q2 of 2016.Eli Lilly - co to pursue new standard-of-care changing therapies that target tumor dependencies in molecularly enriched populations.Eli Lilly - will now focus on 7 pipeline assets for priority internal development and 3 additional assets which are pending data from ongoing trials​.Eli Lilly And Co sees FY capital expenditures about $1.1 billion.Eli Lilly And Co - co to also ‍build rational combinations that overcome resistance, and develop next-generation immunotherapies in oncology research​.  Full Article

Lilly and Incyte provide update on baricitinib
Tuesday, 25 Jul 2017 06:15am EDT 

July 25 (Reuters) - Incyte Corp :Incyte Corp - ‍length of time to a resubmission for New Drug Application(NDA) anticipated to be a minimum of 18 months​.Incyte Corp - ‍FDA has indicated that a new clinical study is necessary for a resubmission in order to further characterize benefit/risk across doses​.Says ‍resubmission to FDA for NDA for baricitinib will be delayed beyond 2017​.Incyte Corp - ‍request for an additional clinical study does not impact ongoing clinical trials for baricitinib​.‍Christi Shaw, president of Lilly Bio-Medicines, says "We are disappointed that resubmission will not occur this year"​.Incyte - Lilly's Christi Shaw says ‍disagree with FDA's conclusions, believe existing data demonstrates positive profile supporting baricitinib approval.  Full Article

Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358
Monday, 24 Jul 2017 07:30am EDT 

July 24 (Reuters) - Eli Lilly and Co ::Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358, an autoimmune therapy.Says Nektar will get initial payment of $150 million, is eligible for up to $250 million additional development & regulatory milestones.Says co, Nektar to co-develop NKTR-358 with Nektar responsible for completing Phase 1 clinical development.Says co, Nektar will share Phase 2 development costs 75 percent Lilly and 25 percent Nektar.Says Nektar will have option to participate in Phase 3 development on an indication-by-indication basis for NKTR-358.Co to be responsible for all costs of global commercialization for NKTR-358; Nektar to have option to co-promote in U.S. under some conditions.Says subject to closing of deal, co expects to incur acquired in-process research and development charge to earnings in 2017 of about $0.09 per share.Says there will be no change to co's 2017 non-GAAP earnings per share guidance as a result of Nektar transaction.FY2017 earnings per share view $4.12 -- Thomson Reuters I/B/E/S.  Full Article

Adimab says entered into agreement to transfer adimab platform to Lilly
Tuesday, 18 Jul 2017 09:00am EDT 

July 18 (Reuters) - Eli Lilly And Co :Adimab - entered into agreement with Eli Lilly to transfer Adimab platform to Lilly for discovery & optimization of antibody-based drugs in therapeutic areas.  Full Article

Eli lilly reaches settlement agreement in U.S. Cialis patent litigation
Wednesday, 12 Jul 2017 10:00am EDT 

July 12 (Reuters) - Eli Lilly And Co ::Lilly reaches settlement agreement in U.S. Cialis patent litigation.Says as part of agreement, Cialis exclusivity is now expected to end at earliest on September 27, 2018..Says ‍as part of agreement, cialis exclusivity is now expected to end at earliest on September 27, 2018.​.Says no change to company's 2017 financial guidance or mid-term expectations through remainder of decade as a result of this settlement​.Says there will be no change to company's 2017 financial guidance or mid-term expectations through remainder of decade as a result of this settlement.Says patent expiration for Adcirca still expected on Nov. 21, or on May 21, 2018, if U.S. FDA grants co's application for pediatric exclusivity.  Full Article

UK Supreme Court confirms ruling on Lilly's patent case
Wednesday, 12 Jul 2017 05:14am EDT 

July 12 (Reuters) - Eli Lilly And Co :UK Supreme Court confirms that products by Actavis would infringe Lilly's patent, dismisses Actavis' cross-appeal.  Full Article

FDA grants priority review for Lilly's abemaciclib
Monday, 10 Jul 2017 06:45am EDT 

July 10 (Reuters) - Eli Lilly And Co ::FDA grants priority review for Lilly's abemaciclib for the treatment of advanced breast cancer.Eli Lilly And Co - ‍lilly intends to submit abemaciclib to European regulators in Q3 of 2017 and to Japanese regulators before end of 2017​.Eli Lilly And Co - ‍working closely with fda and anticipates agency action on the application in Q1 of 2018 for abemaciclib​.  Full Article


CVS Health's dull third-quarter forecast overshadows profit beat

CVS Health Corp forecast current quarter profit below Wall Street estimates and said it has been ordered to cooperate with investigations into possible false claims submitted to a government healthcare program and drug pricing.